Novartis's dispersible ACT treatment set to improve malaria treatment in children
This article was originally published in Scrip
Executive Summary
A new formulation of the malaria treatment Coartem designed specifically for children has been developed and launched by Novartisand the Medicines for Malaria Venture(MMV).